Fotemustine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Fotemustine
Fotemustine.svg
Systematic (IUPAC) name
(RS)-diethyl (1-{[(2-chloroethyl)(nitroso)carbamoyl]amino}
ethyl)phosphonate
Clinical data
AHFS/Drugs.com International Drug Names
Legal status
?
Identifiers
CAS number 92118-27-9 N
ATC code L01AD05
PubChem CID 104799
DrugBank DB04106
ChemSpider 94600 YesY
UNII GQ7JL9P5I2 YesY
KEGG D07255 YesY
ChEMBL CHEMBL549386 YesY
Chemical data
Formula C9H19ClN3O5P 
Mol. mass 315.691 g/mol
 N (what is this?)  (verify)

Fotemustine is a nitrosourea alkylating agent approved for use in the treatment of metastasising melanoma. A study[1] has shown that fotemustine produces improved response rates and but does not increase survival (over dacarbazine in the treatment of disseminated cutaneous melanoma. Median survival was 7.3 months with fotemustine versus 5.6 months with DTIC (P=.067). There was also toxicity prevalence in fotemustine arm. The main toxicity was grade 3 to 4 neutropenia (51% with fotemustine v 5% with DTIC) and thrombocytopenia (43% v 6%, respectively).

External links[edit]

  1. ^ Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, Weichenthal M (March 2004). Fotemustine Compared With Dacarbazine in Patients With Disseminated Malignant Melanoma: A Phase III Study 22 (6). doi:10.1200/JCO.2004.04.165. PMID 15020614.